“There is a surge of momentum for the GlycoMark test as more healthcare professionals, hospitals, and universities—both in the U.S. and internationally—recognize the utility of GlycoMark to indicate recent hyperglycemic episodes and glycemic variability,”
New York, NY (PRWEB) April 28, 2017
GlycoMark, Inc. announced today a partnership with Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S.
GlycoMark is the only clinically available blood test that specifically indicates recent hyperglycemia in patients with diabetes. The GlycoMark test provides a clinically proven one- to two-week measure of hyperglycemic excursions, often related to post prandial glucose peaks.
“There is a surge of momentum for the GlycoMark test as more healthcare professionals, hospitals, and universities—both in the U.S. and internationally—recognize the utility of GlycoMark to indicate recent hyperglycemic episodes and glycemic variability,” said Hirotaka “Hiro” Ishibashi, COO of GlycoMark, Inc. “GlycoMark offers insight into hyperglycemia that traditional tests reflecting mean glucose levels, such as A1C, cannot.”
The agreement with Shiel Medical Laboratory provides even broader access to the GlycoMark test as it possesses a significant regional presence in the states of New York and New Jersey, and has now expanded into the Connecticut and Pennsylvania markets.
The GlycoMark test is a CE-marked and FDA cleared test that provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma, for intermediate-term monitoring of glycemic control in people with diabetes. The test is for professional use, and is not intended to diagnose or prevent any specific diabetes state or disease. Since its discovery, 1,5-AG has been described in more than 600 scientific and medical publications. GlycoMark, Inc. is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan) and Nippon Kayaku Co., Ltd. (Tokyo, Japan) and is dedicated to the discovery and commercialization of novel biomarkers for diabetes. Visit http://www.glycomark.com.